Alignment Healthcare, Inc. (NASDAQ:ALHC) Insider Dawn Christine Maroney Sells 30,000 Shares

Alignment Healthcare, Inc. (NASDAQ:ALHC) insider Dawn Christine Maroney sold 30,000 shares of the stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $10.77, for a total value of $323,100.00. Following the completion of the sale, the insider now owns 1,726,097 shares of the company’s stock, valued at $18,590,064.69. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Dawn Christine Maroney also recently made the following trade(s):

• On Thursday, August 22nd, Dawn Christine Maroney sold 7,074 shares of Alignment Healthcare stock. The stock was sold at an average price of $9.02, for a total value of $63,807.48.
• On Thursday, August 15th, Dawn Christine Maroney sold 20,000 shares of Alignment Healthcare stock. The shares were sold at an average price of $8.70, for a total transaction of $174,000.00.
• On Friday, July 19th, Dawn Christine Maroney sold 36,700 shares of Alignment Healthcare stock. The shares were sold at an average price of $10.01, for a total transaction of $367,367.00.

Alignment Healthcare Stock Up 8.7 %

NASDAQ:ALHC opened at $11.80 on Thursday. Alignment Healthcare, Inc. has a twelve month low of $4.46 and a twelve month high of $12.36. The firm has a market capitalization of $2.26 billion, a price-to-earnings ratio of -14.05 and a beta of 1.47. The company has a quick ratio of 1.61, a current ratio of 1.61 and a debt-to-equity ratio of 1.70. The stock’s 50 day moving average price is $10.17 and its two-hundred day moving average price is $8.27.

Alignment Healthcare (NASDAQ:ALHC) last issued its earnings results on Thursday, August 1st. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.01. The business had revenue of $681.29 million for the quarter, compared to the consensus estimate of $637.66 million. Alignment Healthcare had a negative net margin of 6.85% and a negative return on equity of 101.10%. The firm’s revenue for the quarter was up 47.3% on a year-over-year basis. During the same period in the previous year, the company earned ($0.15) earnings per share. Equities research analysts expect that Alignment Healthcare, Inc. will post -0.67 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Alignment Healthcare

A number of institutional investors and hedge funds have recently modified their holdings of ALHC. Jacobs Levy Equity Management Inc. bought a new position in Alignment Healthcare during the first quarter worth about $918,000. Vanguard Group Inc. lifted its position in shares of Alignment Healthcare by 1.0% in the first quarter. Vanguard Group Inc. now owns 9,239,472 shares of the company’s stock valued at $45,828,000 after buying an additional 93,262 shares during the last quarter. Deerfield Management Company L.P. Series C boosted its stake in shares of Alignment Healthcare by 31.8% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 10,901,485 shares of the company’s stock worth $85,250,000 after acquiring an additional 2,630,788 shares during the period. Bank of New York Mellon Corp increased its holdings in shares of Alignment Healthcare by 27.5% in the second quarter. Bank of New York Mellon Corp now owns 382,462 shares of the company’s stock valued at $2,991,000 after purchasing an additional 82,559 shares during the last quarter. Finally, Principal Financial Group Inc. acquired a new position in Alignment Healthcare in the 1st quarter valued at about $57,000. 86.19% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. TD Cowen boosted their price objective on shares of Alignment Healthcare from $8.00 to $10.00 and gave the company a “buy” rating in a research report on Tuesday, August 6th. Stifel Nicolaus boosted their price target on Alignment Healthcare from $9.00 to $12.00 and gave the company a “buy” rating in a report on Friday, July 26th. Robert W. Baird increased their price objective on Alignment Healthcare from $10.00 to $11.00 and gave the stock an “outperform” rating in a report on Wednesday, August 14th. Barclays boosted their target price on Alignment Healthcare from $4.50 to $7.00 and gave the company an “underweight” rating in a research note on Monday, August 5th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $10.00 price target (up from $8.00) on shares of Alignment Healthcare in a research note on Tuesday, August 6th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, six have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Alignment Healthcare currently has a consensus rating of “Moderate Buy” and an average price target of $9.83.

Alignment Healthcare Company Profile

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.